Purpose: The aims of this study were to evaluate the efficacy and safety of S-1 versus cisplatin (CDDP)þS-1 in patients with completely resected stage II and IIIA non-small cell lung cancer, and to identify predictive biomarkers whose expression in the tumors was significantly associated with patient outcome.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Complete surgical resection is the most effective strategy for early-stage NSCLC. However, the 5year survival rate of patients with completely resected NSCLC of pathologic stages I to IIIA ranges from 32.8% to 83.9% (1) . The main reason for this poor outcome is development of distant metastasis, so controlling the micrometastases that are assumed to be present at the time of surgery with adjuvant drug therapy may lead to improvements in overall survival (OS) rates.
In the past decade, several randomized phase III studies have demonstrated that adjuvant cisplatin (CDDP)-based chemotherapy improves OS in patients with pathologic stage II and IIIA NSCLC (2) (3) (4) . Pignon and colleagues reported an 11% reduction in the risk of death with the use of CDDP-based chemotherapy. However, they also observed a small number of deaths related to chemotherapy toxicity and cardiopulmonary complications (5) , mainly caused by CDDP. Thus, a challenge for researchers is to develop safer and more efficacious treatment regimens.
In Japan, it has been shown that adjuvant chemotherapy with tegafur-uracil (UFT, Taiho Pharmaceutical Co. Ltd) improves 5and 7-year survival rates in patients with completely resected stage I adenocarcinoma (6) . Fluoropyrimidines, such as tegafur, are known to have time-dependent antitumor effects (7) (8) (9) , and it is thought that long-term postoperative administration will be beneficial. However, how useful UFT will be in postoperative adjuvant chemotherapy for patients at more advanced disease stages is not clear (10, 11) .
S-1 (TS-1, Taiho Pharmaceutical Co. Ltd), which consists of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:0.4:1 (12, 13) , is a modified version of UFT. Gimeracil is added to reduce the degradation of tegafur by inhibiting dehydropyrimidine dehydrogenase, and oteracil is added to lower fluoropyrimidine levels in the gut to reduce gastrointestinal toxicity. A phase II study of combination chemotherapy with S-1 and CDDP for previously untreated patients with advanced NSCLC showed an objective response of 47%, and a median survival time (MST) of 11.2 months (14) . A recent phase III trial demonstrated that CDDPþS-1 was not inferior to CDDPþdocetaxel in terms of OS in patients with advanced NSCLC (15) . Although S-1 is more active and toxic than UFT (16) , it can be administered for a year as a postoperative adjuvant therapy for gastric cancer, resulting in prolongation of both PFS and OS when compared with surgery alone (17) . Thus, it would be useful to know how good long-term S-1 is as an adjuvant therapy for patients with stage II-III lung cancer who would otherwise be candidates for cisplatin doublet chemotherapy.
In this randomized phase II trial, we compared long-term S-1 monotherapy (S) with CDDPþS-1 (CS) in patients with completely resected pathologic stage II and III NSCLC, hypothesizing that long-term S-1 would be at least as effective as cisplatin doublet. Although the fact that fluoropyrimidine is a time-dependent drug makes CDDPþlong-term S1 appear to be an attractive alternative, we decided to abandon this strategy over concerns about increased toxicity due to long-term administration of S-1.
Even with cisplatin doublet adjuvant therapy, the survival benefit 5 years after surgery is about 5%, meaning that the remaining 95% of patients experience no benefit. This has led to a search for biomarkers that would allow selection of patients who were suitable for adjuvant chemotherapy as a co-primary endpoint.
Materials and Methods
Patients with completely resected stage II or IIIA (metastasis to a single mediastinal lymph node only) NSCLC, as classified according to the TNM staging system version 6, aged 20 to 74 years, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 were eligible. Patients had to have adequate bone marrow and organ function. The main exclusion criteria were a history of drug allergies, interstitial pneumonia, and concomitant malignancies: heart failure, uncontrolled diabetes mellitus, and active infections. Patients who had undergone a pneumonectomy were also excluded. Written informed consent was obtained from all patients, and the study protocol was approved by the Institutional Review Board of each participating institution.
This study is registered on the UMIN Clinical Trial Database (Study ID: 000001658).
Procedures
Selected patients were randomly assigned to receive either oral S-1 (40 mg/m 2 twice per day) on day 1 to 14 every 3 weeks for a year (S group), or CDDP (60 mg/m 2 ) on day 1 plus oral S-1 (40 mg/m 2 twice per day) on 14 consecutive days repeated every 3 weeks for four cycles (CS group). Patients were required to start the protocol treatment within 8 weeks after surgery. Randomization (minimization method) was done at the central datacenter, and the stratification factors were pathologic disease stage (II vs. IIIA), type of histology (adenocarcinoma vs. others), and institutions. The primary endpoints were relapse-free survival (RFS) at 2 years, and identification of molecules whose expression was significantly associated with patient outcome. Secondary endpoints included OS, rate of adverse events/side effects, and medical treatment completion rate. Relapse was assessed by means of PET and a CT scan of the chest at 6, 12, 18, and 24 months after initiation of the protocol treatment.
Biomarker analysis
cDNA extracted from macro-dissected formalin-fixed paraffinembedded specimens was obtained from 197 of 200 patients. Thirty genes, including 18 whose expressions have been reported to be potentially associated with CDDP (e.g. ERCC1, XRCC1, BRCA1, GSTpi, HMG1, and TBP), and 12 genes associated with fluoropyrimidine sensitivity (TS, DHFR, DPD, UMPS, and UPP1; Table 1 ), were measured by mass spectrometry (QGE analysis MassArray). Primer sequences for each gene are available on request.
Statistical analysis
In this study, we expected the 2-year RFS rates for II-IIIA to be 50% in both groups. In order to obtain a precision of approximately AE 10% width in 95% confidence intervals (95% CIs), a total of 100 patients per group were required. The following decision rules were adopted: if the Bayesian posterior probability that the 2-year RFS would exceed a threshold value of 40% was less than 0.85, neither regimen merited further evaluation; if only one regimen had a probability of more than 0.85, then that regimen merited further study; if both regimens had probabilities of more than 0.85, no formal comparison of the two 2-year RFSs was made, but the decision was made on the basis of information about the secondary endpoints.
Translational Relevance
S-1 is an oral anticancer agent that consists of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:0.4:1. In this randomized phase II trial, we compared long-term S-1 monotherapy with cisplatinþS-1 in patients with completely resected pathologic stage II and III non-small cell lung cancer and explored predictive biomarkers. The primary endpointrelapse-free survival at 2 years-was similar in both groups, and the toxicities were mild in the S-1 group. We identified expression levels of uridine monophosphate synthase (UMPS) as a predictive biomarker for long-term S-1 monotherapy. We were also able to confirm the utility of UMPS in in vitro and in vivo experiments. Our study suggests that long-term S1 monotherapy is an attractive adjuvant therapy option and that UMPS is a useful biomarker for identifying patients most likely to benefit from it.
The Kaplan-Meier method was used to estimate the RFS and OS curves of the treatment groups. The 95% CIs of 2-year RFS were estimated according to the Greenwood formula. Stratified Cox regression with histology (adenocarcinoma vs. other) and pathologic stage (II vs. III) as strata was applied to estimate the HR between the two groups. All efficacy analyses were done for the full analysis set, which was defined as all randomly assigned patients with confirmed eligibility. Safety analyses were done for patients who were actually treated with at least one dose.
To evaluate potential biomarkers, the expression of each gene was dichotomized according to its median value of expression. P values for interaction between expression levels (high/low) and treatment groups were calculated using a Cox proportional hazards model. As we thought the power of statistical tests for interaction would be low due to the small number of relapses and deaths in this phase II study, we did not adopt a rigorous statistical threshold to take account of multiple comparisons. Instead, our strategy was to perform confirmatory in vitro and in vivo studies of promising but potentially false-positive genes identified in the current study. All P values are reported as two tailed, and statistical analyses were conducted with SAS (version 9.2, SAS Institute).
Creation of UMPS expressing cells in vitro
Plasmid constructs expressing Uridine monophosphate synthetase (UMPS) were generated in pIRES2-ZsGreen1 vectors (Clontech). Cells were transfected with empty pIRES2-ZsGreen1 or pIRES2-ZsGreen1-UMPS using FuGENE 6 (Roche Diagnostics). Forty-eight hours after transfection, the virus was harvested. NIH3T3 mouse fibroblasts and A549 lung adenocarcinoma cells were purchased from the ATCC. A549 cells were authenticated by short tandem repeat at Takara Bio Inc. These cells were maintained in RPMI-1640 (Sigma) supplemented with 10% heat-inactivated FBS, and were infected with viral supernatants; the GFP-positive cells were then sorted. The stable viral transfectant cells in each cell line were designated as NIH3T3-mock, NIH3T3-UMPS, A549mock, and A549-UMPS.
In vitro growth inhibition assay
Cells were transferred to 96-well flat-bottomed plates and cultured for 24 hours before exposure for 72 hours to various concentrations of 5-FU, as indicated. Attached cells were fixed and then stained for 10 minutes with 0.5% crystal violet. The stain was eluted with 0.05 mol/L sodium dihydrogenphosphate dehydrate, and the absorbance at 540 nm was measured with a spectrophotometer. Tumors cells (5 Â 10 6 ) were injected subcutaneously into the axilla of athymic nude mice (BALB/c nu/nu, CLEA Japan). Treatment was initiated when tumors in each group of 6 mice achieved an average volume of 100 to 200 mm 3 . S-1 was administered orally 5 days per week for 4 weeks at doses of 5 and 8.3 mg/kg. 5-FU was administered intraperitoneally 5 days per week for 4 weeks at doses of 10 and 20 mg/kg. Tumor volume was determined from measurements of tumor length (L) and width (W) according to the following formula: LW 2 /2. Both tumor size and body weight were measured twice per week.
Results

Patient characteristics
A total of 200 patients from 30 institutions in Japan were enrolled in the study between September 2007 and December 2009 ( Fig. 1 ). More than half of the patients were enrolled from the top five contributing institutions. The baseline demographic characteristics of the subjects were well balanced between the two treatment groups, except that the patients in the CS group had higher rates of extensive lymph node dissection and stage IIA disease, and a lower rate of IIB disease ( Table 2 ). Because 3 patients in the S-1 group and 5 patients in the CDDP þ S-1 group did not receive any chemotherapy, 192 patients were eligible for the safety analysis ( Fig. 1) .
Delivered chemotherapy
In total, 51 patients (52.6%) completed 15 cycles of adjuvant chemotherapy in the S-1 group, and 71 patients (74.7%) completed four cycles of adjuvant chemotherapy in the CDDPþS-1 group. The median relative dose intensities were high in both the S-1 (85.2%) and CDDPþS-1 groups (86.4% and 94.1%, respectively). The main reasons for discontinuation of the protocol treatment were patient withdrawal and medical decision based on toxicity (data not shown) in both groups, and recurrence in the S-1 group. The dose of S-1 was reduced for 25 of the 96 patients (26%) in the S group, whereas the dose of CDDP was reduced for 10 patients because of nonhematologic toxicities.
Survival analyses
In the 197 patients evaluated, a total of 89 relapses were observed. The 2-year RFS rate (one of the co-primary endpoints) was 65.6% (95% CI, 55.3-74.0%) in the S-1 group and 58.1% (47.7-67.2%) in the CDDPþS-1 group (Fig. 2A) . The Bayesian posterior probability that the 2-year RFS would exceed a threshold value of 40% was 99.9% in the S-1 group and 99.9% in the CDDPþS-1 group. The HR between the two groups by stratified Cox regression was 0.90 (0.59-1.37). The 5-year OS rates of the two groups were also comparable: 72.6% (95% CI, 64.3-82.0) in the S-1 group and 72.2% (95% CI, 63.8-81.7) in the CDDPþS-1 group (Fig. 2B ).
Safety
Toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0. The incidence of anemia or neutropenia of grade 3 or 4 was significantly lower among the patients in the S-1 group than among those in the CDDP þ S-1 group (anemia: 1.0% vs. 8.4%; neutropenia: 13.4% vs. 27.4%, respectively; Table 3 ). As for nonhematologic toxicities, grade 3 or 4 anorexia and nausea occurred more commonly in the CDDPþS-1 group than in the S-1 group (anorexia: 9.5% vs. 2.1%; nausea: 6.3% vs. 0%; febrile neutropenia: 5.3% vs. 0%, respectively). Conversely, treatment with S-1 was associated with a higher rate of grade 1 or 2 skin rash than treatment with CDDPþS-1 (26.8% vs.9.5%, respectively). There were 17 deaths in the S-1 group and 18 deaths in the CDDPþS-1 group during the study period, but they were not treatment related.
Biomarkers
There were 14 genes whose expression levels were below the detection limit in more than half of the patients, and these genes were not subjected to further analyses (Table 1 ). Of the remaining 16 genes, the only one with interaction of P < 0.05 was UMPS (also known as orotate phosphorybosyl transferase; OPRT; P ¼ 0.0348; Table 1 ). P values of <0.1 were obtained for DPD, UPP1, ERCC6, and HMG1. RFS at 2 years (95% CI) in patients with high levels of UMPS/OPRT was 69% (95% CI, 54-80%) in the S group and 53% (37-66%) in the CS group (Fig. 2C) , whereas 2-year RFS in patients with low levels was 64% (49-76%) in the S group and 61% (46-73%) in the CS group (Fig. 2D ). However, molecules such as ERCC1 and GSTpi (18, 19) , whose expressions have previously been associated with CDDP sensitivity, did not emerge as predictive markers (P ¼ 0.7908, 0.6406, respectively).
Confirmation of UMPS as a predictive factor for pyrimidine sensitivity in vitro and in vivo UMPS/OPRT could have been falsely identified as a predictive biomarker on the basis of a P value of <0.05. Therefore, we decided to evaluate the effect of UMPS/OPRT overexpression on fluoropyrimidine sensitivity in vitro and in vivo. Overexpression of UMPS was confirmed by Western blotting (Fig. 3A) .
Overexpression of UMPS made the A549 lung cancer cell line about 100 times more sensitive to 5-FU in vitro (Fig. 3B) . In vivo experiments also confirmed that UMPS/OPRT is a determinant of sensitivity to 5FU as well as S-1 (Fig. 3C ).
Discussion
The purpose of this randomized phase II study was to compare the efficacy of an oral fluoropyrimidine, S-1, with that of S-1 plus CDDP in adjuvant chemotherapy for NSCLC in two groups of patients. The primary endpoint, RFS at 2 years, was similar in both groups. The secondary endpoint, OS at 5 years, was also similar in both groups, and was reproducibly observed. The Bayesian posterior probability that 2-year RFS would exceed 40% was more than 99% in both groups.
The adverse events associated with S-1 and CDDPþS-1 were as expected: treatment with CDDPþS-1 resulted in higher incidences of neutropenia of grade 3 or 4 (27.4%) and anemia (8.4%) than treatment with S-1 alone, which gave incidences of only 13.4% and 1%, respectively. However, we found CDDPþS-1 to be less toxic than the results of previous adjuvant trials had indicated: grade 3-4 neutropenia was noted in 73% of subjects in the Adjuvant Navelbine International Trialist Association trial (ANITA) and the National Cancer Institute of Canada JBR.10 trial (3, 4) , respectively, and grade 4 neutropenia was found in 17.5% of patients in the International Adjuvant Lung Trial (IALT; ref. 2). In terms of nonhematologic toxicity, CDDPþS-1 produced higher incidences of febrile neutropenia, anorexia, nausea, and vomiting. In contrast, S-1 resulted in a higher incidence of skin rash. However, the toxicities were mild and controllable. There were no treatment-related deaths in either of our groups, although the sample size was admittedly small. Treatment-related deaths were reported in the previous trials (IALT: 0.8%, JBR.10: 0.8%, ANITA: 2%).
Although medication compliance of UFT at one year in a previous adjuvant trial was 74% (6), more than half (53%) of our patients received S-1 for a year. That S-1 had a favorable toxicity profile and produced survival outcomes comparable with those of CDDPþS-1 suggests that long-term administration is feasible.
As a co-primary endpoint, we were able to identify UMPS/ OPRT as a promising predictive biomarker for S-1 monotherapy. UMPS/OPRT catalyzes the conversion of 5FU to fluorouridine monophosphate (FUMP), which is a precursor of the active metabolites fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine monophosphate (FUMP; ref. 20) . Thus, high UMPS/OPRT expression appears to enhance the effect of 5FU. Indeed, SNPs and expression levels of UMPS/ OPRT have been reported to predict the efficacy and toxicity of 5FU in other human cancers and cell lines (21) (22) (23) . Several reports on NSCLC treated with 5FU have shown associations between expression levels of UMPS/OPRT and clinical outcomes (24, 25) .
Conflicting opinions exist regarding the expression of OPRT and the response to oral 5-FU-derivative agents. Nakano and colleagues reported that the 5-year survival rate of patients with OPRT-positive stage II to III tumors was significantly higher than that of patients with OPRT-negative tumors (24) . Conversely, Takeda and colleagues reported that there is no significant association between tumor response and expression levels of OPRT (25) . Our findings indicate that high UMPS/OPRT expression might identify a subset of patients who would benefit from S-1 rather than CDDPþS-1, even though both the monotherapy and combination groups received S-1. Our explanation is that susceptibility to UMPS/OPRT activity depends on differences in the length of treatment with S-1 (i.e., 1 year vs. 12 weeks), and hence differences in the total dose of S-1. However, the clinical relevance of UMPS/OPRT to NSCLC treated with S-1-based chemotherapy has not been established. Further prospective studies of these biomarkers are necessary to confirm clinical outcomes and benefits. In conclusion, this study suggests that adjuvant long-term S-1 monotherapy or CDDPþS-1 for completely resected stage II-III NSCLC is a viable alternative to cisplatin doublet chemotherapy in terms of efficacy and toxicity. UMPS/OPRT expression may be a useful marker for identifying patients who would benefit most from adjuvant long-term S-1, although the fact that we did not adjust for multiple testing may limit the relevance of this finding. We plan to conduct a randomized phase III trial to compare adjuvant chemotherapy with S1 monotherapy versus CDDPþvinorelbine for completely resected stage II-III NSCLC. 
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